| Literature DB >> 32722206 |
Zuzanna Lewicka-Potocka1,2, Alicja Dąbrowska-Kugacka1, Ewa Lewicka1, Rafał Gałąska2, Ludmiła Daniłowicz-Szymanowicz1, Anna Faran1, Izabela Nabiałek-Trojanowska1,2, Marcin Kubik1, Anna Maria Kaleta-Duss1, Grzegorz Raczak1.
Abstract
It has been raised that marathon running may significantly impair cardiac performance. However, the post-race diastolic function has not been extensively analyzed. We aimed to assess whether the marathon run causes impairment of the cardiac diastole, which ventricle is mostly affected and whether the septal (IVS) function is altered. The study included 34 male amateur runners, in whom echocardiography was performed two weeks before, at the finish line and two weeks after the marathon. Biventricular diastolic function was assessed not only with conventional Doppler indices but also using the heart rate-adjusted isovolumetric relaxation time (IVRTc). After the run, IVRTc elongated dramatically at the right ventricular (RV) free wall, to a lesser extent at the IVS and remained unchanged at the left ventricular lateral wall. The post-run IVRTc_IVS correlated with IVRTc_RV (r = 0.38, p < 0.05), and IVRTc_RV was longer in subjects with IVS hypertrophy (88 vs. 51 ms; p < 0.05). Participants with measurable IVRT_RV at baseline (38% of runners) had longer post-race IVRTc_IVS (102 vs. 83 ms; p < 0.05). Marathon running influenced predominantly the RV diastolic function, and subjects with measurable IVRT_RV at baseline or those with IVS hypertrophy can experience greater post-race diastolic fatigue.Entities:
Keywords: amateur runners; diastolic function; isovolumic relaxation time; marathon run; myocardial performance index; relaxation; right ventricle
Mesh:
Year: 2020 PMID: 32722206 PMCID: PMC7432325 DOI: 10.3390/ijerph17155336
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Echocardiographic parameters of the left and right ventricle obtained in amateur marathon runners.
| Parameter | Stage I | Stage II | Stage III | ANOVA | Post-Hoc | |
|---|---|---|---|---|---|---|
| Mean ± SD 1 or | Stage | Stage | ||||
| LV EF (%) | 61.8 ± 4.9 | 60.5 ± 4.4 | 60.7 ± 4.5 | * 0.38 | - | - |
| LV GLS (%) | −19.9 ± 2.3 | −19.4 ± 2.1 | −19.7 ± 2.2 | * 0.41 | - | - |
| RV 4CSL (%) | −22.0 ± 2.8 | −20.80 ± 2.6 | −21.49 ± 2.5 | * <0.05 | <0.05 | 0.46 |
| TAPSE (mm) | 25.0 ± 3.6 | 24.0 ± 3.7 | 25.0 ± 2.7 | * 0.56 | - | - |
| RV FAC (%) | 43 (37; 45) | 39 (35; 44) | 41 (36; 45) | ^ 0.19 | - | - |
| RVd MID (cm) | 3.4 ± 0.6 | 3.7 ± 0.5 | 3.5 ± 0.5 | * <0.01 | <0.01 | 0.08 |
| RVd BAS (cm) | 3.8 ± 0.4 | 3.8 ± 0.5 | 3.9 ± 0.5 | * 0.44 | - | - |
| LVd BAS (cm) | 4.8 ± 0.4 | 4.6 ± 0.3 | 4.9 ± 0.3 | * <0.001 | <0.01 | 0.88 |
| RVd/LVd BAS | 0.77 ± 0.1 | 0.82 ± 0.1 | 0.79 ± 0.1 | * <0.05 | <0.05 | 0.59 |
1—when normally distributed; 2—when non-normally distributed; Stage I—two weeks before the marathon run; Stage II—at the marathon finish line; Stage III—two weeks after the marathon run; LV —left ventricular; EF—ejection fraction; GLS—global longitudinal strain; RV—right ventricular; 4CSL—four-chamber longitudinal strain = global strain; TAPSE—tricuspid annular plane systolic excursion; FAC—fractional area change; RVd MID—RV mid-cavity end-diastolic dimension; LVd BAS—LV basal end-diastolic diameter; RVd BAS—RV basal end-diastolic diameter; RVd/LVd BAS—basal RV to LV end-diastolic diameter ratio; SD—standard deviation; * ANOVA with post-hoc Tukey test if applicable; ^ Friedman ANOVA with post-hoc average rank test if applicable.
Left ventricular parameters obtained by means of the pulsed wave Doppler and spectral Doppler tissue imaging in amateur marathon runners.
| Parameter | Stage I | Stage II | Stage III | ANOVA | Post-Hoc | |
|---|---|---|---|---|---|---|
| Mean ± SD 1 or | Stage | Stage | ||||
| S’_LW (cm/sec) | 11 ± 3 | 11 ± 3 | 11 ± 3 | * 0.88 | - | - |
| E’_LW (cm/sec) | 15 (12; 17) | 12 (10; 15) | 14 (13; 16) | ^ <0.001 | <0.05 | ns |
| A’_LW (cm/sec) | 8 (7;9) | 10 (9; 11) | 8 (7; 9) | ^ <0.001 | <0.05 | ns |
| E’/A’_LW | 1.8 (1.4; 2.1) | 1.2 (1.0; 1.5) | 1.9 (1.6; 2.3) | ^ <0.001 | <0.05 | ns |
| IVRT_LW (ms) | 53 ± 17 | 54 ± 19 | 56 ± 15 | * 0.99 | - | - |
| IVRTc_LW | 53 ± 17 | 59 ± 23 | 54 ± 15 | * 0.28 | - | - |
| MPI_LW | 0.41 ± 0.08 | 0.45 ± 0.17 | 0.42 ± 0.07 | * 0.20 | - | - |
| S’_IVS (cm/sec) | 8 (8; 9) | 9 (8; 10) | 9 (7; 10) | ^ 0.24 | - | - |
| E’_IVS (cm/sec) | 11 ± 2 | 10 ± 2 | 11 ± 2 | * <0.001 | <0.01 | 0.73 |
| A’_IVS (cm/sec) | 8 (8; 10) | 10 (9; 11) | 8 (7; 10) | ^ <0.001 | <0.05 | ns |
| E’/A’_IVS | 1.3 ± 0.4 | 1.0 ± 0.3 | 1.4 ± 0.4 | * <0.001 | <0.001 | 0.26 |
| IVRT_IVS (ms) | 82 (65; 95) | 80 (68; 94) | 78 (64; 86) | ^ 0.46 | - | - |
| IVRTc_IVS | 78 (66; 92) | 92 (77; 108) | 73 (65; 85) | ^ <0.001 | <0.05 | ns |
| MPI_IVS | 0.55 (0.44; 0.59) | 0.53 (0.44; 0.6) | 0.47 (0.44; 0.54) | ^ 0.09 | - | - |
| E_MV (cm/sec) | 71 (67; 87) | 67 (55; 77) | 78 (68; 92) | ^ <0.01~ | ns | ns |
| A_MV (cm/sec) | 51 ± 10 | 65 ± 14 | 56 ± 11 | * <0.001 | <0.001 | 0.29 |
| E/A_MV | 1.5 ± 0.4 | 1.1 ± 0.3 | 1.5 ± 0.4 | * <0.001 | <0.001 | 0.7 |
| E_MV/E’_LW | 5.4 ± 1.2 | 5.5 ± 1.6 | 5.6 ± 1.8 | * 0.66 | - | - |
| E_MV/E’_IVS | 7.1 ± 1.5 | 7.0 ± 1.8 | 7.6 ± 2.0 | * 0.34 | - | - |
| E_MV/E’_AVG | 6.3 (5.2; 7.0) | 5.8 (5.0; 7.2) | 6.2 (5.4; 7.3) | ^ 0.74 | - | - |
1—when normally distributed; 2—when non-normally distributed; LW—parameter measured at the lateral mitral annulus; IVS—parameter measured at the septal mitral annulus; S’—peak systolic tissue velocity; E’—peak early diastolic tissue velocity; A’—peak atrial diastolic tissue velocity; IVRT—isovolumic relaxation time; IVRTc—IVRT adjusted for heart rate; MPI—myocardial performance index; MV—mitral inflow; E—peak early flow velocity; A—peak atrial flow velocity; AVG—averaged for parameters obtained at IVS and LW; ns-p-value of >0.05 of post-hoc average rank test for Friedman ANOVA; ~ ANOVA test p <0.05, but post-hoc test revealed the difference between stages II and III, which was not the question of our study. * ANOVA with post-hoc Tukey test if applicable; ^ Friedman ANOVA with post-hoc average rank test if applicable. For other abbreviations, see Table 1.
Right ventricular parameters obtained by means of the pulsed wave Doppler and spectral Doppler tissue imaging in amateur marathon runners.
| Parameter | Stage I | Stage II | Stage III | ANOVA | Post-Voc | |
|---|---|---|---|---|---|---|
| Mean ± SD 1 or | Stage | Stage | ||||
| S’_RV (cm/sec) | 14 (13; 16) | 14 (13.5; 16) | 15 (13; 16) | ^ 0.51 | - | - |
| E’_RV (cm/sec) | 12 (11; 15) | 12 (9; 14) | 14 (13; 16) | ^ <0.05 ~ | ns | ns |
| A’_RV (cm/sec) | 13 (10; 14) | 16 (13; 20) | 13 (12; 16) | ^ <0.01 | <0.05 | ns |
| E’/A’_RV | 1.0 (0.9; 1.2) | 0.7 (0.6; 0.9) | 1.2 (0.9; 1.3) | ^ <0.001 | <0.05 | ns |
| IVRT_RV (ms) | 0 (0; 29) | 52 (32; 70) | 21 (9; 34) | ^ <0.001 | <0.05 | ns |
| IVRTc_RV (ms) | 0 (0; 27) | 58 (39; 78) | 20 (0; 35) | ^ <0.001 | <0.05 | ns |
| MPI_RV | 0.28 (0.22; 0.37) | 0.48 (0.35; 0.64) | 0.33 (0.25; 0.41) | ^ <0.001 | <0.05 | ns |
| E_TV (cm/sec) | 55 ± 13 | 49 ± 11 | 56 ± 11 | * 0.18 | - | - |
| A_TV (cm/sec) | 33 ± 10 | 46 ± 15 | 31 ± 8 | * <0.001 | <0.001 | 0.99 |
| E/A_TV | 1.7 ± 0.4 | 1.2 ± 0.3 | 1.9 ± 0.6 | * <0.001 | <0.001 | 0.55 |
| E_TV/E’_RV | 4.5 ± 1.1 | 4.2 ± 1.7 | 3.9 ± 1.0 | * 0.44 | - | - |
1—when normally distributed; 2—when non-normally distributed; RV—right ventricular parameters measured at the lateral tricuspid annulus; TV—transtricuspid inflow. * ANOVA with post-hoc Tukey test if applicable; ^ Friedman ANOVA with post-hoc average rank test if applicable. For other abbreviations, see Table 1 and Table 2.
Figure 1Changes in the right ventricular isovolumic relaxation time (IVRT_RV) between the three study stages. (a) IVRT_RV was undetectable at stage I (two weeks before the marathon run) and (c) at stage III (two weeks after the competition); (b) in contrast, the appearance of IVRT_RV and its prolongation up to 104 ms at stage II (at the marathon finishing line).
Figure 2Changes in the heart rate-adjusted isovolumic relaxation time between the three stages of the study, assessed in the spectral Doppler tissue imaging (a) at the lateral tricuspid annulus (IVRTc_RV), (b) at septum (IVRTc_IVS) and (c) at the lateral mitral annulus (IVRTc_LW).